s6y

Aspira Women's Health Inc.

Ticker
AWHL
CIK
926617
Industry
In Vitro & In Vivo Diagnostic Substances
Formerly
VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC

Financials 126

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Mar 31, 2025
  10. 10-K Annual Report for period ending Dec 31, 2024

All 126 financials filings

News 393

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K/A Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K/A Current report filing
  10. 8-K Current report filing

All 393 news filings

Ownership 727

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4/A Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4/A Statement of changes in beneficial ownership of securities
  8. 4/A Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 727 ownership filings

Prospectus 103

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-1 General form of registration statement for all companies including face-amount certificate companies
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-1/A General form of registration statement for all companies including face-amount certificate companies
  9. S-1/A General form of registration statement for all companies including face-amount certificate companies
  10. S-1 General form of registration statement for all companies including face-amount certificate companies

All 103 prospectus filings

Proxies 87

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEF 14A Definitive proxy statements
  4. DEFR14A Definitive revised proxy soliciting materials
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 87 proxies filings

Other 115

  1. D Exempt (Private) Offering
  2. SCHEDULE 13D/A
  3. ARS Annual report to security holders
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. UPLOAD Letter (PDF)
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. SCHEDULE 13D/A
  10. D Exempt (Private) Offering

All 115 other filings